Ani Pharmaceuticals (ANIP) Accumulated Expenses (2010 - 2026)

Ani Pharmaceuticals has disclosed Accumulated Expenses across 17 years of filings, most recently posting $13.7 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $13.7 million, up 14.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.7 million (up 14.18% YoY), and the FY2025 annual result was $37.9 million, changed 0.46% from the prior year.
• Accumulated Expenses came in at $13.7 million for Q1 2026 at Ani Pharmaceuticals, down from $37.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $37.9 million in Q4 2025 to a low of $5.6 million in Q4 2023.
• The 5-year median for Accumulated Expenses is $13.7 million (2026), against an average of $16.8 million.
• Across the five-year window, Accumulated Expenses plunged 45.64% in 2023 and soared 572.94% in 2024, its largest moves.
• Ani Pharmaceuticals' Accumulated Expenses stood at $10.3 million in 2022, then slumped by 45.64% to $5.6 million in 2023, then jumped by 572.94% to $37.7 million in 2024, then advanced by 0.46% to $37.9 million in 2025, then plunged by 63.76% to $13.7 million in 2026.
• The last three Accumulated Expenses figures came in at $13.7 million (Q1 2026), $37.9 million (Q4 2025), and $33.2 million (Q3 2025), per Business Quant data.